Real-world data on PD-1 inhibitor therapy in metastatic melanoma

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Levin Max 1969) > Real-world data on ...

LIBRIS Formathandbok (Information om MARC21)

Details
MARC

Fältnamn	Indikatorer	Metadata
000		04151naa a2200409 4500
001		oai:gup.ub.gu.se/281986
003		SwePub
008		240528s2019 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://gup.ub.gu.se/publication/2819862 URI
024	7	a https://doi.org/10.1080/0284186x.2019.16209662 DOI
040		a (SwePub)gu
041		a eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Arheden, A.4 aut
245	1 0	a Real-world data on PD-1 inhibitor therapy in metastatic melanoma
264		c 2019-05-31
264	1	b Informa UK Limited,c 2019
520		a Introduction: Phase III studies of PD-1 inhibitors have demonstrated remarkable improvements in the survival of patients with metastatic melanoma (MM). If these results are generalizable to an unselected patient population treated in clinical routine is unknown. This study aimed to investigate and describe clinical efficacy and safety of PD-1 inhibitors in patients with MM treated in routine clinical practice. Material and methods: A retrospective descriptive study of patients with metastatic or inoperable cutaneous melanoma treated with PD-1 inhibitors at a single institution (Department of Oncology, Sahlgrenska University Hospital) from 1 September 2015 to 31 August 2017. Data were obtained from medical records. Results: A total of 116 patients were included in the analyses. The overall survival (OS) at 12-month follow-up was 70.2% and the median OS was 27.9 months. Patients with BRAF mutated tumors had increased OS, whereas ECOG PS >= 2, LDH > ULN and presence or history of brain metastases (stage M1d) were associated with impaired survival. Immune-related AEs of any grade occurred in 64 (55.2%) patients and 15 (12.9%) patients experienced immune-related AEs of grades 3 and 4. Notably, rheumatic adverse events occurred at a higher rate (15.5%) than previously reported. The occurrence of immune-related AEs was associated with a benefit in OS, while the severity of immune-related AEs did not affect survival, nor did the use of systemic corticosteroids. Conclusions: The efficacy and safety of PD1 inhibitors in routine clinical practice appear comparable to that described in clinical trials.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653		a nivolumab
653		a ipilimumab
653		a braf
653		a Oncology
700	1	a Skalenius, J.4 aut
700	1	a Bjursten, Sarau Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xbjurs
700	1	a Stierner, Ulrika,d 1952u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xstiul
700	1	a Ny, Lars,d 1967u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xnylai
700	1	a Levin, Max,d 1969u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xlevma
700	1	a Jespersen, Henriku Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xjeshe
710	2	a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för onkologi4 org
773	0	t Acta Oncologicad : Informa UK Limitedg 58:7, s. 962-966q 58:7<962-966x 0284-186Xx 1651-226X
856	4	u https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2019.1620966?needAccess=true
856	4 8	u https://gup.ub.gu.se/publication/281986
856	4 8	u https://doi.org/10.1080/0284186x.2019.1620966

Find in a library

Acta Oncologica (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Arheden, A.; Skalenius, J.; Bjursten, Sara; Stierner, Ulrika ...; Ny, Lars, 1967; Levin, Max, 1969; show more...; Jespersen, Henri ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Articles in the publication: Acta Oncologica

By the university: University of Gothenburg

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se